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Abstract
Background: The Contact Heat Evoked Potential Stimulator (CHEPS) rapidly stimulates cutaneous small
nerve fibres, and resulting evoked potentials can be recorded from the scalp. We have studied patients
with symptoms of sensory neuropathy and controls using CHEPS, and validated the findings using other
objective measures of small nerve fibres i.e. the histamine-induced skin flare response and intra-epidermal
fibres (IEF), and also quantitative sensory testing (QST), a subjective measure.
Methods: In patients with symptoms of sensory neuropathy (n = 41) and healthy controls (n = 9) we
performed clinical examination, QST (monofilament, vibration and thermal perception thresholds), nerve
conduction studies, histamine-induced skin flares and CHEPS. Skin punch biopsies were immunostained
using standard ABC immunoperoxidase for the nerve marker PGP 9.5 or the heat and capsaicin receptor
TRPV1. Immunoreactive IEF were counted per length of tissue section and epidermal thickness recorded.
Results: Amplitudes of Aδ evoked potentials (μV) following face, arm or leg stimulation were reduced in
patients (e.g. for the leg: mean ± SEM – controls 11.7 ± 1.95, patients 3.63 ± 0.85, p = 0.0032). Patients
showed reduced leg skin flare responses, which correlated with Aδ amplitudes (rs = 0.40, p = 0.010). In
patient leg skin biopsies, PGP 9.5- and TRPV1-immunoreactive IEF were reduced and correlated with Aδ
amplitudes (PGP 9.5, rs = 0.51, p = 0.0006; TRPV1, rs = 0.48, p = 0.0012).
Conclusion: CHEPS appears a sensitive measure, with abnormalities observed in some symptomatic
patients who did not have significant IEF loss and/or QST abnormalities. Some of the latter patients may
have early small fibre dysfunction or ion channelopathy. CHEPS provides a clinically practical, non-invasive
and objective measure, and can be a useful additional tool for the assessment of sensory small fibre
neuropathy. Although further evaluation is required, the technique shows potential clinical utility to
differentiate neuropathy from other chronic pain states, and provide a biomarker for analgesic
development.
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Background
Small fibre neuropathy is commonly caused by diabetes,
and also a number of other conditions, including amy-
loid, HIV, neurotoxin exposure and hereditary and idio-
pathic diseases. The presenting features may include pain,
numbness, or hypersensitivity in the peripheral limb, usu-
ally the feet, progressing proximally in a length-depend-
ent fashion, with or without autonomic symptoms.
Diagnosis of sensory peripheral neuropathy is usually by
nerve conduction studies, which assess mainly large sen-
sory fibre dysfunction. To assess small sensory fibre func-
tion, methods such as thermal quantitative sensory testing
(QST) are commonly applied.
The Contact Heat Evoked Potential Stimulator (CHEPS)
technology utilizes rapidly delivered heat pulses with
adjustable peak temperatures to stimulate the differential
warm/heat thresholds of receptors expressed by Aδ and C
fibres. The resulting evoked potentials can be recorded
and measured. CHEPS has been used to selectively excite
Aδ and C fibres in human volunteer glabrous and hairy
skin [1]. Contact heat evoked potentials have also been
studied previously in volunteer models, where reliable
and quantifiable evoked potentials were produced, with
consistent Aδ peak latencies and amplitudes particularly
in the Cz component, and with significant correlation to
pain intensity scores [2,3]. Volunteer models have been
used to illustrate the reproducibility of cerebral responses
(blood oxygen level dependent fMRI changes) and subjec-
tive responses (pain scores) to different intensities of
CHEPS stimuli [4]. A strong similarity between CHEPS
evoked potentials and Laser Evoked Potentials has been
described [5]; CHEPS offers the advantages of being easier
to use in the clinic, does not require eye protection, and
reduces risk of inducing burns or erythema. It also allows
for repetitive stimulation or 'wind-up'. CHEPS thus offers
an additional clinical tool for the assessment of small sen-
sory nerve fibre function.
We have studied 41 patients with a clinical diagnosis of
sensory fibre neuropathy, focussing on CHEPS in compar-
ison with other objective tests such as histamine-induced
skin flares and intra-epidermal fibre (IEF) counts in skin
biopsies. The flare following intradermal histamine injec-
tion (axon-reflex vasodilatation) is mediated by mainly
by C fibres, which release neuroeffectors such as calci-
tonin gene-related peptide (CGRP) and substance P from
skin terminals, with consequent vasodilatation and
extravasation. The flare is a component of the classical
Lewis' triple response, and can be used for the assessment
of small sensory fibre loss or dysfunction [6-10]. Intra-epi-
dermal nerve fibre density on skin biopsy has been
described previously as a valid objective method for quan-
titative assessment of small fibre neuropathy, and is
regarded as the preferred test [11-13]. We have included
TRPV1 nerve fibre counts in this study, as CHEPS activates
cutaneous nerve terminals which express TRPV1, the heat
and capsaicin receptor, in the protocol we have used.
Methods
Patients
Forty one patients with a clinical diagnosis of sensory neu-
ropathy [mean age years 55 (range 36–77); 25 female]
were studied. All patients were seen in the neuropathy
clinic at Hammersmith Hospital. All procedures were
undertaken with full patient written consent and approval
of the Hammersmith Research Ethics Committee. The
mean duration of symptoms was 4.7 years (range 4
months – 17 years). The majority of patients (n = 29) had
idiopathic neuropathy; of the remaining 12, one had glu-
cose intolerance detected 3 years after onset of symptoms,
three patients were early diabetics, two had treated vita-
min B12 deficiency, two a previous history of statin use,
two a history of moderate alcohol intake, one a recent his-
tory of chemotherapy, and one a history of vasculitis.
Thirty four patients had painful neuropathy, and most
were taking treatment at the time of review – twelve were
taking Gabapentin, five Pregabalin, six Amitryptyline and
a single prescription each of Paroxetine, Mexiletine, Clon-
azepam, Levetiracetam. However, no patients experienced
sedation at the time of the study, and future systematic
studies are indicated to determine the effect of medica-
tions. The mean age of control subjects was 43.6 years
(range 21 to 70).
Full history, clinical examination, contact heat evoked
potentials, skin flare response to histamine, and skin
punch biopsies were performed in all patients. Nerve con-
duction studies of the sural and peroneal nerve were car-
ried out, although not all at the same institution. Values
less than 5 μV amplitude and 40 m/s conduction velocity
were considered abnormal for the antidromic sural sen-
sory action potential and values less than 3 mV amplitude
and 40 m/s conduction velocity were considered abnor-
mal for the common peroneal nerve (compound muscle
action potential from extensor digitorum brevis). Quanti-
tative Sensory Tests (QST) were also performed, including
monofilament, vibration and thermal perception thresh-
olds, as described previously [14-16]. Thresholds for
touch were measured using Semmes-Weinstein hairs
(made by A. Ainsworth, University College London, UK).
The number of the hair with the lowest force reliably
detected by the patient (at least 3 out of 5 trials) on the
dorsum of the most affected big toe was recorded. The
'abnormal' value was designated as >No. 3 monofilament
(0.0479 g). Vibration perception thresholds were meas-
ured using a biothesiometer (Biomedical instrument Co.,
Newbury, OH, USA) placed on the metatarsophalangeal
joint of the big toe. Three ascending and three descending
trials were carried out, and the mean value obtained. TheBMC Neurology 2007, 7:21 http://www.biomedcentral.com/1471-2377/7/21
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vibration threshold was expressed in volts; values >12 V
were considered 'abnormal'. Thermal perception thresh-
olds were performed as previously described using Ther-
motest (Somedic, Stockholm, Sweden). A 15 × 25 mm
thermode was used and thermal thresholds determined at
the lateral calf for warm and cool perception from a base-
line temperature of 30°C, with a change in temperature of
1°C/sec. The mean of three consecutive tests for each
modality was recorded. Values >6.4°C for warm sensa-
tion, >2.3°C for cool sensation were considered abnor-
mal.
Contact heat evoked potentials
We used a Contact Heat Evoked Potentials Stimulator
(CHEPS), (Medoc Ltd, Ramat Yishai, Israel) with a ther-
mode area of 572.5 mm2, and a heating thermo-foil
(Minco Products, Inc., Minneapolis, MN) covered with a
25 μm layer of thermo-conductive plastic (Kapton®, ther-
mal conductivity at 23°C of 0.1 – 0.35 W/m/K). The ther-
mode heating rate was 70°C/s and the cooling rate 40°C/
s. The baseline temperature was 32°C, destination tem-
perature 51°C, and stimulus interval 7 seconds. In this
paper we have focused on Aδ amplitudes, as they provided
the most robust signal.
Evoked potentials were recorded from six midline elec-
trodes (Fz, FCz, Cz, CPz, Pz, POz), using a similar proto-
col to that described previously [1]. The ground electrode
was placed on the left temporal region. Each recording
epoch of 2800 ms included a period of 200 ms baseline
before stimulus onset. A low cut off filter with a time con-
stant of 1.06103 and a frequency of 0.15 Hz and a high
cut off filter of 100 Hz were applied. The impedance from
all electrodes was maintained below 5 Ω and the electro-
encephalogram (EEG) recorded and digitized at a sam-
pling rate of 500 Hz. We report data from the vertex (FCz)
position for Aδ potentials following skin stimulation.
The recorded EEG data were analysed using Vision Ana-
lyser©  Version 1.05.001 (Brain Products, Ltd., London
UK). Recordings of eye movement artefacts from supra-
and infra-orbital electrodes were subtracted from the cer-
ebral trace, and the mean of resulting sweeps obtained.
Within each waveform, the latency was measured from
the first definitive negative peak (N2), and the amplitude
measured peak-to-peak (N2 to P2). The sweep speed used
when the waveform was measured was 225 ms per cm.
Histamine skin flare
Histamine (0.03 ml of 1 mg/ml. Martindale Pharmaceuti-
cals, Romford, UK) was injected intra-dermally into the
lateral calf of patients (n = 41) and controls, as described
previously [14], and the area of flare measured after 10
minutes by scanning Laser Doppler imaging (Moor
Instruments Ltd, Axminster UK). On the flux image the
region of interest (defined by the edge of the flare) was
drawn, and the area measured using the Moor Laser Dop-
pler Imager (LDI) version 3.11 software [10].
Skin Biopsies
Two 3 mm diameter skin punch biopsies were collected
under local anaesthesia from the leg (lateral calf) of
patients (n = 41) and control subjects (n = 9) for immu-
nohistology. Skin biopsy was taken from the same area as
was used for CHEPS stimulation.
Immunohistology
The immunohistochemical methods and antibodies used
have been reported by us previously [7,17,18]. One of the
two skin biopsies was snap frozen and stored at -70°C,
and the other immersed in fixative (modified Zamboni's
fluid – 2% formalin; 0.01 M phosphate buffer; 15% satu-
rated picric acid pH 7.2), then washed in phosphate buff-
ered saline (PBS; 0.1 M phosphate; 0.9% w/v saline; pH
7.3) containing 15% w/v sucrose for an hour, before snap
freezing in embedding medium (Tissue-Tek OCT, RA
Lamb, Sussex, U.K.).
Frozen sections (10 μm) of pre-fixed and unfixed samples
were collected onto poly-L-lysine-coated (Sigma, Poole,
Dorset UK) glass slides. Unfixed sections were then post-
fixed in freshly prepared, 4% w/v paraformaldehyde in
PBS. All sections were washed in PBS, and endogenous
peroxidase blocked by incubation in 0.3% w/v hydrogen
peroxide in methanol. After rehydration, the tissue sec-
tions were incubated overnight with primary antibodies
to the structural nerve marker PGP 9.5 (Ultraclone Ltd,
Isle of Wight, UK; 1/50,000; for immersion fixed tissue
sections) or the heat and capsaicin receptor TRPV1 (Glax-
oSmithKline, Harlow, UK; 1/5,000, for post-fixed tissue
sections). Immersion fixed sections were used for optimal
staining of PGP 9.5, and frozen, post-fixed sections were
used for optimal immunostaining of TRPV1. Controls
included omission of primary antibodies, or their replace-
ment with pre-immune serum. Sites of antibody attach-
ment were revealed using a nickel-enhanced,
immunoperoxidase method (avidin-biotin complex –
ABC elite; Vector Laboratories, High Wycombe, Bucks.,
U.K.). Nuclei were counterstained with 0.1% w/v aqueous
neutral red. Intra-epidermal and sub-epidermal fibres
immunoreactive for PGP 9.5 and TRPV1 were counted in
a blinded manner, from up 4 – 5 sections from each
biopsy, and the length of the epidermis measured using a
calibrated microscope eyepiece graticule. Results were
expressed as fibres per mm length of epidermis.
Epidermal thickness was quantified from post-fixed fro-
zen tissue sections (10 μm). One section was randomly
selected for each control or patient, and epidermal thick-
ness measured at three points along the length of the epi-BMC Neurology 2007, 7:21 http://www.biomedcentral.com/1471-2377/7/21
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dermis using a calibrated microscope, eyepiece graticule
and a × 40 objective. Epidermal thickness was defined as
the distance between the epidermal-dermal junction and
the outermost stratum corneum.
Statistical Analysis
Graphs were created and statistical tests (Mann Whitney
and Spearman correlation coefficients) were performed
using GraphPad Prism version 3.02 for Windows, (Graph-
Pad Software, San Diego California USA).
Results
Clinical examination and QSTs
Thirty four patients complained of pain related symp-
toms, of which "burning" was the most frequent descrip-
tion (n = 15). The spontaneous or on-going pain score
using a numeric rating scale (NRS, where 0 is no pain and
10 is maximum pain) was 7.4 (range 4.2 – 9). Ten patients
complained of numbness in the distal lower limbs, and 2
patients, additionally, in the hands; 10 patients reported
lower limb skin hypersensitivity (to either mechanical or
thermal stimuli). None of the patients had weakness or
muscle wasting. Ten patients had reduced ankle jerks. No
patient had abnormality of light touch (cotton wool) sen-
sation. Sixteen patients had reduced pinprick sensation in
the distal lower limb. Twenty patients had elevated mono-
filament perception thresholds. Twenty patients had ele-
vated vibration perception threshold. Analysis of results
from patients revealed the mean warm perception thresh-
old as 8.2 ± 0.8°C change and cool perception threshold
as 3.6 ± 0.6°C change at the calf. Thermal perception
thresholds were within normal limits in 20 patients for
warming, and in 21 patients for cooling. Nerve conduc-
tion studies showed abnormalities in 7 patients for sural
nerve sensory action potentials; all motor studies were
normal.
Contact heat evoked potentials
Examples of an evoked potential trace from a control sub-
ject and a patient are shown in Figure 1. Evoked potentials
recorded from patients showed reduced Aδ amplitudes
compared to controls (Leg Aδ amplitude, mean μV ± SEM,
controls 11.7 ± 1.95, patients 3.63 ± 0.85, p = 0.0032; Arm
Aδ amplitude, controls 13.67 ± 2.21, patients 8.28 ± 1.48,
p = 0.034; Face Aδ amplitude, controls 20.75 ± 2.32,
patients 13.14 ± 1.59, p = 0.02: Figure 2). In 24 patients
there were no recordable evoked potentials on stimula-
tion of the leg, and in some cases of the arm (n = 13) and
face (n = 4). In contrast, evoked potentials were easily
recordable in all control subjects from all regions. Sixteen
patients with thermal perception thresholds within nor-
mal limits had reduced Aδ amplitudes of evoked poten-
tials in the leg (defined as < mean – SEM of controls).
Contact Heat Evoked Potential Aδ amplitudes following stim- ulation of the face, arm and leg of controls (white bars) and  patients (black bars) Figure 2
Contact Heat Evoked Potential Aδ amplitudes following stim-
ulation of the face, arm and leg of controls (white bars) and 
patients (black bars). * = 0.034, ** p = 0.02, *** p = 0.0032.
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Contact Heat Evoked Potentials (Aδ) from a control subject  (left panel) and a patient (right panel) on stimulation of differ- ent regions (reported from FCz electrode) Figure 1
Contact Heat Evoked Potentials (Aδ) from a control subject 
(left panel) and a patient (right panel) on stimulation of differ-
ent regions (reported from FCz electrode). Latencies (ms); 
Control: Face 380, Arm 410, Leg 500; Patient: Face 440, Arm 
560, Leg not recordable. Amplitudes (μV); Control: Face 
20.86, Arm 20.07, Leg 14.46; Patient: Face 8.45, Arm 5.22, 
Leg not recordable.BMC Neurology 2007, 7:21 http://www.biomedcentral.com/1471-2377/7/21
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There were no significant differences in latency between
patients and controls for face, arm or leg stimulation (Leg
Aδ latency, ms, mean ± SEM, controls 525 ± 0.017,
patients 509 ± 0.015, p = 0.141; Arm Aδ latency, controls
446 ± 0.009, patients 439 ± 0.020, p = 0.020; Face Aδ
latency, controls 397 ± 0.011, patients 423 ± 0.012, p =
0.56). Evoked potential amplitudes from the face, arm
and leg were not significantly correlated with age in
patients (Face rs = -0.2130 p = 0.2056; Arm rs = -0.01452 p
= 0.9415; Leg rs = -0.01228 p = 0.9627). In this study we
found no relationship between age and amplitude of
evoked responses in controls, but in other studies with
larger numbers of controls an inverse relationship with
age was obtained (data not shown).
There was good reproducibility of evoked potential
latency and amplitude from the same controls on two
occasions (in the morning, and afternoon on the same
day) (n = 4); intra-class correlation coefficient: for latency
= 0.78, amplitude = 0.86). Figure 3 shows two superim-
posed Aδ evoked potentials from the face of a control sub-
ject recorded on different occasions. We have also shown
good reproducibility of control evoked potential ampli-
tude from the arm in a different set of 8 control subjects,
with a significant correlation between the repeated ampli-
tudes on two separate days (rs = 0.8095, p = 0.0218). Cer-
ebral and subjective responses to different intensities of
CHEPS stimulation (sensory detection, pain detection
and pain toleration thresholds) have previously been
shown to be reproducible across individuals and across
multiple sessions [4].
Pain scores (mean ± SEM) from CHEPS application were:
Face – controls 7.4 ± 0.4, patients 6.6 ± 0.57; Arm – con-
trols 6.3 ± 0.6, patients 4.3 ± 1.01; Leg – controls 5.0 ± 0.9,
patients 3.5 ± 0.76. There was no significant difference in
the pain scores between controls and patients for all sites
tested (Face p = 0.0825; Arm p = 0.0641; Leg p = 0.1313).
Histamine-induced flares
Patients showed a reduced mean flare area of response
compared to controls (flare response (cm2) mean ± SEM;
controls 18.14 ± 2.28; patients 12.03 ± 0.90; p = 0.02);
there was no difference between flux units in control and
patient flares (patient flux mean 444 ± 13.7; control flux
454 ± 46.4; p = 0.61).
Skin biopsies
Antibodies to both PGP 9.5 and TRPV1 showed immu-
nostaining of nerve fibres in the dermis and sub-epider-
mis, with fine, branching, intra-epidermal fibres, often
extending to the stratum corneum, in control and patient
biopsies. The number of intra-epidermal PGP 9.5-immu-
noreactive fibres per mm was reduced in patient biopsies
(mean ± SEM; intra-epidermal: controls, 6.52 ± 1.43 (n =
6); patients, 3.76 ± 0.48 (n = 41); p = 0.027 Figure 4a, b).
Intra-epidermal TRPV1-immunoreactive fibres per mm
were significantly reduced (mean ± SEM; intra-epidermal:
controls, 5.7 ± 1.4 (n = 9); patients, 3.45 ± 0.52 (n = 41);
p = 0.04 Figure 4c, d). There was a strong correlation
between numbers of nerve fibres immunostaining for
PGP 9.5 and TRPV1 (rs = 0.6049, p < 0.0001). Prominent
swelling of intra- and sub-epidermal fibres was seen in
only one patient with both nerve markers. Epidermal
thickness measurements revealed a significant reduction
in patient biopsies (mean ± SEM, controls 100.1 ± 15 μm
(n = 12), patients 73.0 ± 2.8 μm (n = 41), p = 0.0143).
Correlations of objective tests and contact heat evoked 
potentials
Histamine-induced flares
A positive correlation was demonstrated between flare
area and evoked potential Aδ amplitudes (rs = 0.40, p =
0.010; Figure 5), and also nerve fibre (PGP 9.5) density (rs
= 0.44, p = 0.0036), but did not just reach significance
Two superimposed Aδ evoked potentials from a control sub- ject on stimulation of the face, recorded on different occa- sions Figure 3
Two superimposed Aδ evoked potentials from a control sub-
ject on stimulation of the face, recorded on different occa-
sions.BMC Neurology 2007, 7:21 http://www.biomedcentral.com/1471-2377/7/21
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between nerve fibre density (TRPV1) and histamine
induced skin flare area in the leg (rs = 0.300, p = 0.053).
There was no statistical correlation between leg flare area
and arm evoked potential Aδ amplitudes (rs = 0.10, p =
0.55).
Skin biopsies
PGP 9.5 and TRPV1 fibre density showed significant pos-
itive correlations with leg evoked potential Aδ amplitudes
(Figure 6; PGP 9.5: rs = 0.51, p = 0.0006, TRPV1: rs = 0.48,
p = 0.0012). When patients with absent evoked potentials
were excluded from the analysis of correlation with PGP
9.5 nerve fibre density, the correlation was also significant
(rs = 0.67, p = 0.004); however, this latter correlation was
not significant for TRPV1 (rs = 0.23, p = 0.36). Correlation
of arm evoked potentials Aδ amplitudes and nerve fibre
density in the calf was also significant when all patients
were included in the analysis (PGP 9.5, rs = 0.46, p =
0.002; TRPV1, rs = 0.35, p = 0.024).
An overview of sensory small fibre test results from the leg
and correlations between tests is shown in Table 1.
Discussion
Objective measures of nociceptor fibre loss or dysfunction
can serve as important tools to help diagnose sensory
small fibre neuropathy, and to distinguish neuropathy
from other chronic pain states. These may also potentially
serve as indicators of analgesic efficacy. The Contact Heat
Evoked Potential Stimulator (CHEPS) can be used to
stimulate a range of heat sensitive receptors expressed by
Aδ and C fibres, and the resulting evoked potentials can
been recorded and measured [1]. To the best of our
knowledge, this is the first time that the use of CHEPS has
been described in patients with small fibre neuropathy.
Contact heat evoked potentials recorded from patients
with small fibre sensory neuropathy were of substantially
reduced Aδ amplitude from the face, arm and leg, in com-
parison with controls.
In this study we have focused on Aδ amplitudes as they
provided the most robust signal; C fibre traces were also
obtained but were less robust. Aδ amplitudes for our con-
trols were slightly lower than those recorded by
Granovsky et al (2005), however, we have used a more
Plot of patient intra-epidermal nerve fibres (PGP 9.5) in skin  biopsies and Contact Heat Evoked Potential Aδ amplitudes  after leg stimulation Figure 6
Plot of patient intra-epidermal nerve fibres (PGP 9.5) in skin 
biopsies and Contact Heat Evoked Potential Aδ amplitudes 
after leg stimulation.
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Intra-epidermal fibres for both the nerve marker – (PGP 9.5;  a, b) and capsaicin receptor (TRPV1; c, d) are reduced in  patient's skin Figure 4
Intra-epidermal fibres for both the nerve marker – (PGP 9.5; 
a, b) and capsaicin receptor (TRPV1; c, d) are reduced in 
patient's skin. Scale bar = 50 μm.
Plot of histamine induced flare area vs. Contact Heat Evoked  Potential Aδ amplitudes after leg stimulation Figure 5
Plot of histamine induced flare area vs. Contact Heat Evoked 
Potential Aδ amplitudes after leg stimulation.
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proximal site for thermode placement (i.e. volar forearm
arm, compared to thenar eminence or dorsum of hand).
The apparent abnormalities of small sensory fibre func-
tion in our patients observed with the contact heat evoked
potentials measurements were validated by demonstrat-
ing correlations with other objective measures – skin IEF
fibre counts and histamine-induced flares. Reduction of
PGP 9.5 and TRPV1 IEF showed a significant correlation
with leg evoked Aδ potential amplitudes. A significant
positive correlation was also demonstrated between skin
flare area and leg evoked potential Aδ amplitude. CHEPS
appears to be a sensitive measure, detecting abnormalities
in some patients with clinical symptoms, but who are
within normal limits for other tests, including thermal
thresholds – while it may be speculated that the decrease
or absence of contact heat evoked potentials in such
patients may indicate early small fibre dysfunction (possi-
bly due to a mechanism other than axonal degeneration –
such as a sensory ion channelopathy), further studies are
necessary to explore and confirm these possibilities. Skin
biopsies and flares have the advantage over CHEPS and
QST in that they localise the pathology within the periph-
eral nervous system. QST may reveal additional phenom-
ena such as paradoxical sensations (burning sensation on
cooling). It should also be noted that subsets of small
fibres may be affected independently in small fibre neu-
ropathies [19], which reflects the heterogeneous aetiology
of the condition. The use of a full array of tests to assess
and localise small fibre dysfunction is thus desirable,
including QST, skin biopsies, skin flares and CHEPS, for
the diagnosis of the condition, and to advance clinico-
pathological correlations.
Skin biopsy is a sensitive method for the quantitative
assessment of small sensory fibres, and has been consid-
ered the "gold standard" for diagnosing small fibre neu-
ropathy [11-13,20,21]. The European Federation of
Neurological Sciences (EFNS) guidelines commend skin
biopsy for this diagnosis in preference to sural nerve
biopsy [22]. However, analysis of skin biopsy is techni-
cally challenging for some investigators; the biopsy leaves
a small scar and has a risk, albeit low, of complications,
for example infection or keloid formation. Skin biopsies
are avoided over some affected regions e.g. the sole, or
palm. Our skin biopsy results compare favourably to oth-
ers utilising skin biopsy with the same tissue section thick-
ness [13].
Epidermal thickness in biopsies taken from our patients
was significantly reduced compared to biopsies taken
from controls, in keeping with a diagnosis of neuropathy.
It is well known that denervation of the skin causes thin-
ning of the epidermis and this has been illustrated exper-
imentally in rat [23-25] and mouse models [26].
Swellings of nerve fibres and their varicosities were rarely
observed in our patient cohort. We noted marked swell-
ings on both large and fine calibre nerve fibres in only one
patient in our study. This may reflect the stable symp-
tomatology in most of our patients. The low detection fre-
quency of swellings in our cohort of patients may
alternatively reflect our routine use of 10 μm tissue sec-
tions, although some of our studies using thicker (50 μm)
sections revealed no increase in the number of patients
with this morphological phenomenon. We have seen
higher frequencies of axonal swellings in diagnostic skin
biopsies from patients with more acute neuropathies, in
accord with other reports. Nerve fibre swellings have been
reported previously in rodents and humans [21,27-29].
However, the significance of these morphological changes
is uncertain [30]. Some studies suggest that they predict
nerve degeneration [23,31], and mark the activity of the
neuropathic process or the pre-degeneration of nocicep-
tive fibres. In addition, they have been correlated with the
early development of neuropathic symptoms, abnormal
heat pain thresholds [32], and a decline in the density of
epidermal nerve fibres [33]. Other studies have shown
that swellings are found in regenerated fibres after skin
blister or capsaicin denervation, and have been associated
with improved sensation and re-innervation [30,34].
Table 1: Overview of sensory small fibre tests and correlations. All data presented from the leg.
Patients Controls Correlations
Contact heat evoked potentials Latency (ms) 509 ± 0.015 525 ± 0.017 -
Amplitude (μV) 3.63 ± 0.85 11.7 ± 1.95 • PGP 9.5 and TRPV1 IEF
• Flare area
Skin biopsy (IEF/mm) PGP 9.5 3.76 ± 0.48 6.52 ± 1.43 • Flare area
• Evoked potential amplitude
TRPV1 3.45 ± 0.52 5.7 ± 1.4 • Evoked potential amplitude
Skin flare Area (cm2) 12.03 ± 0.90 18.14 ± 2.28 • PGP 9.5 IEF
• Evoked potential amplitude
QST (°C change) Warm 8.2 ± 0.8 6.3 ± 0.3 -
Heat 13.97 ± 0.6 10.1 ± 0.2 -
Cool 3.6 ± 0.6 2.1 ± 0.1 -BMC Neurology 2007, 7:21 http://www.biomedcentral.com/1471-2377/7/21
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Previous work on the axon reflex flare has shown that C-
nociceptor fibre activation is the main factor determining
its area [35]; the correlation with CHEPS responses sug-
gests parallel pathology in Aδ and C fibres in our patients.
Flares are known to be diminished in patients with small
fibre neuropathies [8-10]. Recently, axon reflex flares have
been shown to represent a potential biomarker for TRPV1
antagonists: a reduction of heat-evoked pain and capsai-
cin-evoked flare area by the TRPV1 antagonist SB705498
was demonstrated in a study of 19 healthy human volun-
teers [36]. CHEPS can be used in areas unsuitable for his-
tamine-induced flares such as the face or glabrous skin.
We have previously reported correlations of nerve growth
factor (NGF), which regulates TRPV1 expression, with
skin flare area in patients with diabetic neuropathy
[14,37].
The EFNS guidelines on neuropathic pain assessment [22]
recommend laser evoked potentials as a reliable method
of assessing nociceptive pathways, and of diagnostic use
in peripheral neuropathy. They have been used success-
fully in studies of patients with peripheral neuropathies
[38], trigeminal neuralgia [39], post herpetic neuralgia
[40], and syringomyelia [41]. Laser evoked potential sup-
pression helps diagnose neuropathic pain states
[39,42,43], while laser evoked potential facilitation is
described in fibromyalgic and chronic inflammatory pain
[44,45]. The similarity between contact heat evoked and
laser evoked potentials has already been described [5].
Lower amplitudes of laser evoked potentials were
reported following stimulation of the trigeminal nerve in
diabetic patients [46], with a number of absent responses
in affected patients, as in our study with contact heat
evoked potentials. Similar changes in laser evoked poten-
tials were also reported following stimulation of the feet
in diabetic patients [47,48] with no clinical or electro-
physiological evidence of large fibre dysfunction. CHEPS
thus appears to produce similar cerebral evoked nocicep-
tor potentials to laser stimulation in patients, at least in
the regions we have tested. In comparison with lasers, the
CHEPS system is easy to operate and calibrate, and it
allows for repetitive stimulation or "wind-up", avoiding
any risk of superficial burns. However, CHEPS does
involve contact with the skin, which may be uncomforta-
ble in some patients with allodynia, and, in principle, the
skin contact may affect pathways not activated by heat or
noxious stimuli. A discussion comparing thermal conduc-
tion and thermal radiation in the study of the nociceptive
system has been conducted [49,50]. Conductive heat
offers the advantage of control over temperature at the
thermode-skin interface (via a thermocouple in the stim-
ulator), and while lasers avoid the simultaneous stimula-
tion of low threshold mechanoreceptors, they can cause
variations in baseline temperatures. Also discussed, was
the problem of estimating the activation temperature at
the nerve receptor level with the CHEPS system. Heat is
dissipated at the skin-thermode due to a heat sink effect,
which is not seen with modern lasers, where varying the
wavelength can change the depth of penetration.
CHEPS could potentially be used as a valuable tool in
future trials of novel therapeutic agents in experimental
pain models, as contact heat evoked potentials may help
monitor the effects of analgesic intervention. It may be
particularly useful in the development of TRPV1 antago-
nists for chronic pain states. TRPV1, a member of the
vanilloid receptor family localizes mainly to small sensory
fibres, and is a ligand-gated ion channel activated by
vanilloids, noxious heat and protons. The association
between TPRV1 immunoreactivity and tissue hypersensi-
tivity has been demonstrated for a number of hypersensi-
tivity states in humans [18,51]. TRPV1 antagonists have
been shown to relieve pain in rodent models [52], and
clinical trials are underway.
Conclusion
In summary, we have shown that the contact heat evoked
potential stimulator (CHEPS) can provide a practical,
rapid and non-invasive additional clinical tool of poten-
tial utility in the evaluation of small fibre neuropathy and
neuropathic pain states. Further evaluation of the tech-
nique is underway to identify a potential role in analgesic
development.
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